Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

One of the biggest drug highlights at the 2015 ADA Scientific Sessions was a compelling presentation by diaTribe scientific Advisory Board member Dr. John Buse on brand...
First-ever SGLT-2/DPP-4 inhibitor drug, will this combination cut costs for patients?
Over seven million Americans have diabetic retinopathy – how Eylea provides another treatment for this serious complication.
How will a new drug fare in a 4,000-patient, four-year study?
Another diabetes drug that helps people lose weight?
Twitter summary: JAMA study shows that metformin is safest first-line therapy for type 2 diabetes – future GRADE study to show best second-line therapy The journal JAMA...
Current trial results show that obese patients using Contrave are about 41% less likely to experience any major heart event (e.g. heart attack, strokes, or heart-related...
After the rapid-acting inhaled insulin Afrezza launched this February, we have been very eager to learn more about how this new product impacts patients’ day-to-day...
ClinicalTrials.gov Identifier: NCT00920582 This study is currently recruiting patients recently diagnosed with type 1 diabetes to investigate the efficacy of teplizumab...
Submitted to the FDA and could be approved this year.
$300 million and counting – how much have we learned from the heart safety trials of Onglyza and Nesina?
Zosano Pharma is making early progress with an innovative patch-based glucagon delivery system for severe hypoglycemia, recently announcing that it has completed...
When might this product reach the market?
Smartphone user interface with no screen or buttons on the pump! Launch: 2018?
And “potentially transformative” advances coming for type 1 diabetes.
New trial testing the inhaled, ultra-rapid insulin in 4-17 year olds.
Flat insulin allows for flexible dosing with lower likelihood of hypoglycemia. How is it priced vs. Levemir?
Praluent now approved for two specific patient populations. How this drug has the future potential to make a big impact on people with diabetes.
Gamechanging Xultophy (Tresiba + Victoza) also now submitted to the FDA.
Launch before the second half of 2016. What savings program will be offered?

Pages